ReviewExpert opinion on biological therapy
Applications of mesenchymal stem cells in ocular surface diseases: sources and routes of delivery.
Review in Expert opinion on biological therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 34 citations in OpenAlex.
- A first-in-human, prospective pilot trial of umbilical cord-derived mesenchymal stem cell eye drops therapy for patients with refractory non-Sjögren's and Sjögren's syndrome dry eye disease.Stem cell research & therapy · 2025Trial
- When Macrophages Heal and When They Scar: Timing in Corneal Fibrosis.Life (Basel, Switzerland) · 2026Review
- Mesenchymal stem cell-derived conditioned medium demonstrates novel antibacterial effects in ocular bacterial infections.Infection and immunity · 2026Article
- Dry Eye Disease: From Mechanisms to Management and Future Directions.Journal of clinical medicine · 2026Review
- Cell and Gene Therapy in Equine Ocular Disease.Veterinary ophthalmology · 2026Review
- In Vivo Evaluation of Injected and Bioprinted Hyaluronic Acid-Based Bioink in Corneal Stromal Pocket.Macromolecular bioscience · 2026Article
- Subconjunctival Injection of Mesenchymal Stem Cells for Corneal Wound Healing After Chemical Injury: Impact on Epithelial Coverage, Limbal Ischemia, and Ocular Surface Inflammatory.Frontiers in medicine · 2026Article
- A biomimetic and xeno-free platform for corneal engineering: synergy between PRGF technology and human dental pulp stem cells.Frontiers in bioengineering and biotechnology · 2026Article
- Tracking adipose-derived mesenchymal stromal cells in the eye: Integrating IVIS imaging and Alu PCR for enhanced detection of human cells.Regenerative therapy · 2025Article
- Cell Free Regenerative Extracellular Vesicle Therapy for Ocular Diseases.Current eye research · 2025Review
- Veterinary Regenerative Medicine: The Evolving Role of Stem Cell-Based Therapies.Stem cell reviews and reports · 2025Review
- Applications of Modern Cell Therapies: The Latest Data in Ophthalmology.Life (Basel, Switzerland) · 2025Review
- Review
- Clinical evidence and critical review of mesenchymal stromal cells for corneal and ocular surface diseases.Stem cells (Dayton, Ohio) · 2025Review
- Timp2-modified gelatinhydroxyphenylpropionic acid hydrogels reverse enhanced scleral recovery and suppress myopia development in mice.Materials today. Bio · 2025Article
- Potential therapeutic applications of stem cells in animal models of ocular affections.Inflammation and regeneration · 2025Review
- Oculoplastic Interventions in the Management of Ocular Surface Diseases: A Comprehensive Review.Life (Basel, Switzerland) · 2025Review
- The revolutionary role of placental derivatives in biomedical research.Bioactive materials · 2025Review
- Identification of glutamine as a potential therapeutic target in dry eye disease.Signal transduction and targeted therapy · 2025Article
- Targeted Therapy for Severe Sjogren's Syndrome: A Focus on Mesenchymal Stem Cells.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionMesenchymal stem cells (MSCs) are novel, promising agents for treating ocular surface disorders. MSCs can be isolated from several tissues and delivered by local or systemic routes. They produce several trophic factors and cytokines, which affect immunomodulatory, transdifferentiating, angiogenic, and pro-survival pathways in their local microenvironment via paracrine secretion. Moreover, they exert their therapeutic effect through a contact-dependent manner. AREAS COVERED: In this review, we discuss the characteristics, sources, delivery methods, and applications of MSCs in ocular surface disorders. We also explore the potential application of MSCs to inhibit senescence at the ocular surface. EXPERT OPINION: Therapeutic application of MSCs in ocular surface disorders are currently under investigation. One major research area is corneal epitheliopathies, including chemical or thermal burns, limbal stem cell deficiency, neurotrophic keratopathy, and infectious keratitis. MSCs can promote corneal epithelial repair and prevent visually devastating sequelae of non-healing wounds. However, the optimal dosages and delivery routes have yet to be determined and further clinical trials are needed to address these fundamental questions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.